CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-014725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yi Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Urology, Guangzhou Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Tumor Microenvironment, Receptors, Interleukin-8B. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China, Guangdong Science and Technology Department.
Abstract (Originalsprache)
Background
Neuroendocrine prostate cancer (NEPC) is characterized by strong immune evasion and profound metabolic reprogramming. A high regulatory T cell (Treg)/CD8 + T cell ratio and an increased proportion of M2/M1 tumor-associated macrophages (TAMs) in the NEPC tumor microenvironment (TME) are associated with poorer progression-free survival, a phenomenon linked to lipid accumulation within the TME. Understanding the regulatory mechanisms governing both the metabolic and immune landscapes of NEPC is critical.
Methods
To investigate these mechanisms, prostate cancer cell lines and patient samples were analyzed using immunohistochemistry, flow cytometry, PCR, western blotting, and mass spectrometry. The interleukin (IL)-8/CXCR2 signaling pathway was targeted for intervention in two tumor-bearing mouse models.
Results
Data revealed that IL-8/CXCR2 signaling drives the accumulation of free fatty acids and very-long-chain polyunsaturated fatty acids, leading to ferroptosis in tumor-infiltrating CD8 + T cells. This, in turn, promotes Treg cell infiltration and an M2 macrophage-dominant immune landscape. Mechanistically, IL-8/CXCR2 signaling upregulates the AKT-mTOR-FAS pathway while activating the mTOR-MYC-ELOVL5 axis via Rictor acetylation. In preclinical studies using NSG and B57BL/6 mouse models, CXCR2 inhibition restored CD8 + T cell antitumor activity and enhanced TAM phagocytosis, significantly reducing tumor growth.
Conclusions
These findings highlight CXCR2 as a promising immunotherapeutic target for NEPC and underscore its relevance in translational medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology, Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Rheumatology and Clinical Immunology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Shanwei, Guangdong, China.
- Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Shanwei, Guangdong, China.
- Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Urology, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Guangdong Science and Technology Department
- Key Research and Development Program Project of Liaoning Province
- Liaoning Provincial Science and Technology Plan Joint Program Key R&D Project
- Natural Science Foundation of Shandong Province
- China Postdoctoral Science Foundation
Zitieren
APA
Sun, Y., Jing, J., Ren, S., Luo, X., Wen, W., Jin, X., Zeng, G., Jiang, X., Zhang, M., & Guo, J. (2026). CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014725
Vancouver
Sun Y, Jing J, Ren S, Luo X, Wen W, Jin X, et al. CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014725
BibTeX
@article{Sun2026,
author = {Sun, Yi and Jing, Jun and Ren, Shangqing and Luo, Xu and Wen, Wei and Jin, Xin and Zeng, Guohua and Jiang, Xuewen and Zhang, Mo and Guo, Ju},
title = {CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-014725}
}
EUVIMED